RGEN

Repligen Corporation provides bioprocessing solutions that enhance process development and manufacturing for the biopharmaceutical industry. The company specializes in technologies for monoclonal antibodies, antibody-drug conjugates, mRNA, plasmid DNA, and viral vectors, focusing on improving yield, reducing risk, and enabling scalable production. Its offerings include upstream filtration, downstream filtration, chromatography, process analytics, and single-use fluid management systems, catering to biopharma and contract development and manufacturing organizations (CDMOs) globally. Repligen's solutions are designed to support both clinical and commercial processes, emphasizing process control and reproducibility.